Axis Direct Assigns Buy Ratings to Three Indian Healthcare Stocks
Axis Direct assigned Buy ratings to Dr Lal PathLabs, Vijaya Diagnostic Centre and Nephrocare Health Services, with target prices implying up to 21% upside.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.